Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated April 7, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing specifically details transactions executed under a programme initiated on February 4, 2026, with an overall authorization of up to DKK 15 billion over a 12-month period.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share buybacks and does not provide operational financial metrics such as revenue, profit, cash flow, margins, or debt levels.
- Share Repurchase Programme Authorization: Up to DKK 15 billion (12-month period starting February 4, 2026).
- Specific Tranche Authorization: Up to DKK 3.8 billion for the period February 4, 2026, to May 4, 2026.
- Total Shares Repurchased (as of April 1, 2026): 9,967,992 B shares.
- Total Transaction Value (as of April 1, 2026): DKK 2,586,404,548.
- Average Purchase Price: DKK 259.47 per B share.
- Treasury Shares Held: 27,357,791 B shares (0.6% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes
Since the last announcement on March 30, 2026, the company executed three additional transactions:
- March 31, 2026: 270,000 shares at DKK 229.85 (Value: DKK 62,060,061).
- April 1, 2026: 270,000 shares at DKK 235.97 (Value: DKK 63,710,841).
- Accumulated Total: The total number of shares repurchased under the current programme increased from 9,162,992 to 9,967,992.
Guidance, Outlook, and Risks
Management expects to continue repurchasing B shares up to the authorized limit of DKK 15 billion during the 12-month period beginning February 4, 2026. The filing notes that the programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules. No specific operational risks, contingencies, or unusual items regarding the company's core business were disclosed in this specific filing.
Investor Verification Checklist
- Verify the remaining authorization under the DKK 15 billion programme (approx. DKK 12.4 billion remaining).
- Confirm the current market price of Novo Nordisk B shares relative to the average repurchase price of DKK 259.47.
- Review the company's full annual report (Form 20-F) for comprehensive revenue, profit, and debt metrics not included in this 6-K.
- Monitor future 6-K filings for updates on the repurchase programme execution through May 2026 and beyond.